PTAB Rules in Favor of Exelixis in Cabometyx Patent Dispute

In a recent decision, the Patent Trial and Appeal Board (PTAB) has favored Exelixis in the ongoing patent dispute concerning its flagship cancer drug, Cabometyx. Azurity Pharmaceuticals, which had sought a review of the patent in question, faced a setback as the PTAB declined their request. This outcome marks a significant moment for Exelixis as it continues to defend its intellectual property rights against challengers in the biotechnology sector. For more details on the ruling, visit the original report by Law360.